- Latest news▼
-
18:22, April 17 First Armenian-German Conference entitled “Heart Failure Spring School”
-
08:38, April 17 Why do kids usually recover from COVID-19 more easily than adults?
-
14:37, April 16 Daily Mail: intermittent fasting is not suitable for children and women before their periods
-
16:41, April 15 Cell: in carriers of defective BRCA2 gene, sugar consumption increases cancer risk
-
15:04, April 15 305 cases of measles recorded in Armenia so far in 2024
-
14:38, April 15 Food and Environmental Virology: tea contributes to effective coronavirus control
-
12:41, April 15 Daily Mail: vitamin A, B3 and E supplements can be dangerous
-
10:56, April 15 Diabetes Care: evening physical activity is good for the heart
-
08:27, April 15 Women are more susceptible to blood loss and death during bypass surgery than men, researchers say
-
18:42, April 13 WHO: Nigeria pioneers revolutionary meningitis vaccine
-
16:43, April 13 One-third of women experience menstruation-related migraines, most often during premenopause - study
-
14:37, April 12 Pediatrics: Hypoglossal nerve stimulation implant helps with sleep apnea
-
12:13, April 12 Health minister: Simulation educational center will be created, assisted reproductive technology capacity will increase in Armenia
-
17:03, April 11 BMJ: antidepressant injection 4 times reduced risk of severe postpartum depression
-
11:35, April 11 Health minister: Number of hard-to-reach medical services within state funding scope increased in Armenia in 2023
All materials
Vaccine against malignant brain tumors passes first phase of clinical trials
A vaccine against malignant brain tumors (diffuse glioma) has passed the first phase of clinical trials. The vaccine was found to be safe and elicited the desired immune response in tumor tissue, the team said in the journal Nature.
According to Newatlas.com, a few years ago, the team developed an artificial version of the IDH1 protein segment with a mutation characteristic of this type of cancer. This mutation-specific peptide vaccine was able to stop the growth of cancer cells with the IDH1 mutation in mice.
As part of the first phase of human testing, the drug was tested in 33 patients with IDH1 mutated gliomas. They received the peptide vaccine in addition to standard treatment. The immune response was assessed in 30 patients.
In 93% of patients, the immune system showed a specific response to the vaccine. The three-year survival rate after treatment was 84% in fully vaccinated patients; in 63% of patients, the tumor did not progress in the same period of time. At the same time, none of the vaccinated had serious side effects.
Follow NEWS.am Medicine on Facebook and Twitter
- Video
- Event calendar
- Archive
- Most read
month
week
day
- BMJ: antidepressant injection 4 times reduced risk of severe postpartum depression 1466
- Pediatrics: Hypoglossal nerve stimulation implant helps with sleep apnea 1334
- Health minister: Simulation educational center will be created, assisted reproductive technology capacity will increase in Armenia 1295
- WHO: Nigeria pioneers revolutionary meningitis vaccine 1134
- One-third of women experience menstruation-related migraines, most often during premenopause - study 1111
- Women are more susceptible to blood loss and death during bypass surgery than men, researchers say 803
- Food and Environmental Virology: tea contributes to effective coronavirus control 786
- Daily Mail: vitamin A, B3 and E supplements can be dangerous 785
- 305 cases of measles recorded in Armenia so far in 2024 748
- Cell: in carriers of defective BRCA2 gene, sugar consumption increases cancer risk 748
- Diabetes Care: evening physical activity is good for the heart 737
- Daily Mail: intermittent fasting is not suitable for children and women before their periods 564
- First Armenian-German Conference entitled “Heart Failure Spring School” 344
- Why do kids usually recover from COVID-19 more easily than adults? 120
- Find us on Facebook
- Poll